Apimeds Pharmaceuticals US APUS
NYSE APUS
$2.88 -0.28 (-8.89%)
As of: Oct 23, 2026 · 2:44 PM EDT

Apimeds Pharmaceuticals US (APUS) Return on Equity [ROE] (2025 - 2026)

Updated

Apimeds Pharmaceuticals US (APUS) recorded Return on Equity [ROE] of -16.29% in Q2 2026, up 76.93 percentage points from -93.22% a year earlier.

Analysis

Apimeds Pharmaceuticals US (APUS) Return on Equity [ROE] (2025 - 2026) Analysis & Trends

For FY2025, Apimeds Pharmaceuticals US reported Return on Equity [ROE] of -15.91%.

  • Quarterly Return on Equity [ROE] has ranged from -93.22% in Q2 2025 to -14.97% in Q4 2025 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,129.96 Bn 1,098.54 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 635.65 Bn 555.51 Bn 17.30 Bn 19.33%
3 AbbVie 504.89 Bn 478.00 Bn 12.70 Bn -
4 Merck 358.50 Bn 312.87 Bn 12.21 Bn 7.21%
5 Novartis Ag 291.04 Bn 255.03 Bn 11.24 Bn 31.52%
6 Astrazeneca 265.27 Bn 238.95 Bn 12.86 Bn 21.39%
7 Amgen 237.76 Bn 193.16 Bn 7.24 Bn 83.75%
8 Gilead Sciences 195.00 Bn 169.20 Bn 6.22 Bn -18.38%
9 Pfizer 171.37 Bn 118.02 Bn 10.94 Bn 4.97%
10 Apimeds Pharmaceuticals US 4.93 Mn -14.70 Mn - -16.29%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -16.29%
Dec 31, 2025 -14.97%
Sep 30, 2025 -57.88%
Jun 30, 2025 -93.22%
API Access

Apimeds Pharmaceuticals US Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=APUS&period=max&api_key=YOUR_API_KEY